# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

#### **SCHEDULE 13G/A**

Under the Securities Exchange Act of 1934 (Amendment No. 1)\*

## BioCryst Pharmaceuticals, Inc.

(Name of Issuer)

#### **Common Stock**

(Title of Class of Securities)

#### 09058V103

(CUSIP Number)

#### December 31, 2019

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

⊠ Rule 13d-1(c)

o Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

CUSIP No. 09058V103	SCHEDULE 13G/A	Page 2 of 9 Pages
CUSIP No. 09058V103	SCHEDULE 13G/A	Page 2 of 9 Pages

1	NAME OF REPORTING PERSONS				
1	Great Point Partners, LLC				
_		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			
2	(a) o (b) o				
	SEC USE ONLY	E ONLY			
3					
	CITIZENSHIP OR PLACE OF ORGANIZATION				
4	USA				
	0011		SOLE VOTING POWER		
		5	0		
	MBER OF		SHARED VOTING POWER		
	SHARES EFICIALLY	6			
	OWNED BY EACH REPORTING		0 SOLE DISPOSITIVE POWER		
RE					
	PERSON WITH		0		
		8	SHARED DISPOSITIVE POWER		
			0		
AGGREGATE AMOUNT BEN		MOUNT B	ENEFICIALLY OWNED BY EACH REPORTING PERSON		
9	0				
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0				
10					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
11	0%				
10	TYPE OF REPORTING PERSON				
12	IA/OO				

CUSIP No. 09058V103	SCHEDULE 13G/A	Page 3 of 9 Pages
CUSIP No. 09058V103	SCHEDULE 13G/A	Page 3 of 9 Page

1	NAME OF REPORTING PERSONS					
1	Dr. Jeffrey R. Jay, M.D.					
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				
2	(a) o (b) o	(a) o (b) o				
	SEC USE ONLY					
3						
	CITIZENSHIP OF	R PLACE (	OF ORGANIZATION			
4	USA					
			SOLE VOTING POWER			
		5	0			
	NUMBER OF SHARES		SHARED VOTING POWER			
	IEFICIALLY WNED BY	6	0			
	EACH REPORTING PERSON		SOLE DISPOSITIVE POWER			
			0			
	WITH	тн 8	SHARED DISPOSITIVE POWER			
			0			
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
9	0					
1.0	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0					
10						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
11	0%					
12	TYPE OF REPORTING PERSON					
12	IN/HC					

CUSIP No. 09058V103	SCHEDULE 13G/A	Page 4 of 9 Pages
CUSIP No. 09058V103	SCHEDULE ISG/A	Page 4 of 9 Pages

1	NAME OF REPORTING PERSONS				
1	Mr. David Kroin				
	CHECK THE API	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			
2	(a) o	(a) o			
	(b) o				
3	SEC USE ONLY				
4	CITIZENSHIP OF	R PLACE (	OF ORGANIZATION		
4	USA	USA			
			SOLE VOTING POWER		
		5	0		
	JMBER OF SHARES		SHARED VOTING POWER		
BEN	IEFICIALLY	6			
O	OWNED BY EACH REPORTING		0 SOLE DISPOSITIVE POWER		
]	PERSON WITH		0		
		8	SHARED DISPOSITIVE POWER		
			0		
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
9	0				
	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 0				
10					
	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
11					
		0% TYPE OF REPORTING PERSON			
12					
	IN/HC				

CUSI	P No. 09058V103	SCHEDULE 13G/A	Page 5 of 9 Pages
Item 1.	(a) Name of Issuer		
	BioCryst Pharmaceuticals, Inc.		
Item 1.	(b) Address of Issuer's Principal Exe	cutive Offices	
	4505 Emperor Blvd., Suite 200 Durham, North Carolina 27703		
Item 2.	(a) Names of Persons Filing:		
	Great Point Partners, LLC Dr. Jeffrey R. Jay, M.D. Mr. David Kroin		
		into a Joint Filing Agreement, dated February 14, 2020, a copporting Persons have agreed to file this statement jointly in account of the components of the	
Item 2.	(b) Address of Principal Business Off	ice:	
	The address of the principal business	s office of each of the Reporting Persons is	
	165 Mason Street, 3rd Floor Greenwich, CT 06830		
Item 2.	(c) Citizenship:		
	Great Point Partners, LLC is a limit the United States. Mr. David Kroin i	ed liability company organized under the laws of the State of Is a citizen of the United States.	Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of
Item 2.	(d) Title of Class of Securities		
	Common Stock		
Item 2.	(e) CUSIP No.:		
	09058V103		
CUSI	P No. 09058V103	SCHEDULE 13G/A	Page 6 of 9 Pages
Item 3.	If this statement is filed pursuant to §	§8240.13d-1(b) or 240.13d-2(b) or (c), check whether the pe	rson filing is a:
(a)	$\square$ Broker or dealer registered under s	ection 15 of the Act (15 U.S.C. 78o);	
(b)	$\square$ Bank as defined in section 3(a)(6)	of the Act (15 U.S.C. 78c);	
(c)	☐ Insurance company as defined in se	ection 3(a)(19) of the Act (15 U.S.C. 78c);	
(d)	☐ Investment company registered uno	der section 8 of the Investment Company Act of 1940 (15 U.S.	C. 80a-8);
(e)	o An investment adviser in accordance	ce with §240.13d-1(b)(1)(ii)(E);	
(f)	☐ An employee benefit plan or endov	wment fund in accordance with §240.13d-1(b)(1)(ii)(F);	
(g)	☐ A parent holding company or contr	ol person in accordance with §240.13d-1(b)(1)(ii)(G);	
(h)	☐ A savings associations as defined i	n Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C	. 1813);
(i)	☐ A church plan that is excluded from U.S.C. 80a-3);	n the definition of an investment company under section 3(c)(1	4) of the Investment Company Act of 1940 (15

(k)  $\square$  A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify

CUSIP No. 09058V103

the type of institution:\_

(j)  $\Box$  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

SCHEDULE 13G/A

Page 7 of 9 Pages

#### 1. Great Point Partners, LLC

- (a) Amount beneficially owned: 0
- (b) Percent of class: 0%
- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or direct the vote: 0
  - (ii) Shared power to vote or direct the vote: 0
  - (iii) Sole power to dispose or to direct the disposition of: 0
  - (iv) Shared power to dispose or to direct the disposition of: 0

#### 2. Dr. Jeffrey R. Jay, M.D.

- (a) Amount beneficially owned: 0
- (b) Percent of class: 0%
- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or direct the vote: 0
  - (ii) Shared power to vote or direct the vote: 0
  - (iii) Sole power to dispose or to direct the disposition of: 0
  - (iv) Shared power to dispose or to direct the disposition of: 0

#### 3. Mr. David Kroin

- (a) Amount beneficially owned: 0
- (b) Percent of class: 0%
- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or direct the vote: 0
  - (ii) Shared power to vote or direct the vote: 0
  - (iii) Sole power to dispose or to direct the disposition of: 0
  - (iv) Shared power to dispose or to direct the disposition of: 0

#### Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

#### Item 6. Ownership of More Than Five Percent on Behalf of Another Person

See Item 4.

### Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not Applicable.

#### Item 8. Identification and Classification of Members of the Group

Not Applicable.

#### Item 9. Notice of Dissolution of Group

Not Applicable.

### Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 09058V103

**SCHEDULE 13G/A** 

Page 8 of 9 Pages

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2020

By: /s/ Dr. Jeffrey R. Jay, M.D.
Dr. Jeffrey R. Jay, M.D., as Senior
Managing Member

Dr. Jeffrey R. Jay, M.D.

/s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D.

Mr. David Kroin

By: /s/ Mr. David Kroin

Mr. David Kroin

CUSIP No. 09058V103	SCHEDULE 13G/A	Page 9 of 9 Pages
---------------------	----------------	-------------------

#### Exhibit A

#### JOINT FILING STATEMENT

#### PURSUANT TO RULE 13d-1(k)

The undersigned hereby agree as follows:

- (i) Each of them is individually eligible to use the Schedule 13G/A to which this Exhibit is attached, and such Schedule 13G/A is filed on behalf of each of them; and
- (ii) Each of them is responsible for the timely filing of such Schedule 13G/A and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Dated: February 14, 2020

#### **Great Point Partners, LLC**

By: /s/ Dr. Jeffrey R. Jay, M.D.

 $\label{eq:def:Dr. Jeffrey R. Jay, M.D., as Senior} Dr. Jeffrey R. Jay, M.D., as Senior$ 

Managing Member

Dr. Jeffrey R. Jay, M.D.

By: /s/ Dr. Jeffrey R. Jay, M.D.

Dr. Jeffrey R. Jay, M.D.

Mr. David Kroin

By: /s/ Mr. David Kroin

Mr. David Kroin